Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany's healthcare sector. Recent investments by Daiichi Sankyo and Eli Lilly underscore Germany's appeal as a hub for pharmaceutical development. read more